GleamWall
中文EN

ACRS Aclaris Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1557746 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-59.3%
TTM net income YoY43.8%
TTM EPS YoY62.7%
Revenue 3-yr CAGR-33.2%
Net income 3-yr CAGR—

Margins

Gross margin79.2%
Operating margin-1,414.0%
Net margin-1,244.1%
FCF margin-1,176.6%
EBITDA margin-1,407.5%

Returns

ROE-55.5%
ROA-40.7%
ROIC (approx.)-59.3%
Asset turnover0.03x

Leverage & solvency

Liabilities / assets22.8%
Debt / equity0.00x
Current ratio5.09x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.94x
Accruals ratio-2.3%
Payout ratio—
Capex / revenue1.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$1.48M$1.63M$2.00M$1.29M$3.30M$1.78M$1.46M$9.21M
Cost of revenue$189,000$218,000$395,000$532,000$538,000$515,000$506,000$705,000
Gross profit$1.29M$1.41M$1.60M$763,000$2.76M$1.26M$949,000$8.51M
R&D expense$16.07M$18.07M$15.66M$16.58M$13.03M$11.45M$11.58M$9.03M
SG&A expense$6.04M$6.05M$6.74M$5.58M$4.87M$5.39M$6.14M$4.95M
Operating income-$21.34M-$24.24M-$22.19M-$22.73M-$17.15M-$18.41M-$18.08M-$99.67M
Pretax income———-$19.80M-$14.61M-$15.43M-$15.09M-$96.55M
Net income-$18.51M-$21.50M-$19.82M-$19.80M-$14.61M-$15.43M-$15.09M-$96.55M
EBITDA-$21.24M-$24.13M-$22.09M-$22.63M-$17.05M-$18.31M-$17.96M-$99.53M
EPS (basic)-0.12-0.15-0.15—-0.12-0.13-0.12—
EPS (diluted)-0.12-0.15-0.15—-0.12-0.13-0.12—
Weighted avg. shares (diluted)149.45M142.74M128.81M—122.62M122.58M122.39M—
Balance sheet
Cash & equivalents$20.39M$19.17M$28.66M$19.96M$25.26M$25.40M$30.36M$24.57M
Short-term investments$93.90M$72.39M$76.76M$70.79M$70.66M$74.40M$74.96M$89.02M
Receivables—————$194,000$250,000$318,000
Current assets$123.23M$97.77M$110.23M$96.32M$100.59M$104.20M$108.79M$125.95M
PP&E, net$624,000$664,000$750,000$761,000$811,000$868,000$942,000$1.01M
Total assets$216.16M$179.69M$198.72M$160.46M$175.53M$189.15M$198.09M$220.33M
Current liabilities$24.22M$28.24M$27.37M$28.64M$25.63M$26.84M$21.51M$31.60M
Total liabilities$49.36M$55.11M$55.07M$57.38M$55.43M$57.41M$54.03M$64.77M
Shareholders' equity$166.80M$124.58M$143.65M$103.08M$120.10M$131.74M$144.07M$155.55M
Shares outstanding150.83M139.82M139.65M120.50M108.34M108.33M108.27M107.85M
Cash flow statement
Operating cash flow-$24.08M-$19.85M-$18.15M-$13.13M-$10.93M-$9.99M-$13.06M-$8.94M
Capital expenditure$13,000$58,000$13,000$24,000$23,000$21,000$43,000$0
Free cash flow-$24.09M-$19.91M-$18.16M-$13.15M-$10.96M-$10.01M-$13.10M-$8.94M
Investing cash flow-$33.22M$10.26M-$30.93M$10.37M$13.83M$5.05M$19.12M-$88.72M
Financing cash flow$58.52M$91,000$57.78M-$2.53M-$3.04M-$9,000-$275,000$74.58M
Depreciation & amortization$100,000$107,000$102,000$102,000$100,000$100,000$128,000$143,000
Stock-based compensation$3.02M$2.67M$3.20M$2.93M$2.86M$3.06M$3.54M$2.86M

Free plan shows the latest 8 periods; Pro shows all 51 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.